Research
Hormonal
GLP-1RA use in patients with metabolically unhealthy obesity (MUHO) is associated with a significantly lower risk of mortality (HR 0.580) compared to non-use.
Clinicians may consider GLP-1RAs for reducing mortality risk in MUHO patients.
StrongSupportsmedium confidence
GLP-1RA use in MUHO was associated with a significantly lower risk of mortality (HR 0.580 [95% CI, 0.566-0.595])
Why this rating
Based on a large cohort study design.
Source
<scp>GLP</scp> ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Tommaso Bucci et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16238
cohort · n=2983151Cited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →